| P50 | author | Jong Sup Park | Q87687285 |
| P2093 | author name string | Jing Chen | |
| | Joon Hyung Kim | |
| | Fernanda Tavares Da Silva | |
| | Dan Bi | |
| | Chul-Jung Kim | |
| | Rok Song | |
| | Kusuma B Gopala | |
| P2860 | cites work | Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women | Q28251260 |
| | HPV vaccination crisis in Japan | Q29036038 |
| | Human papillomavirus is a necessary cause of invasive cervical cancer worldwide | Q29617514 |
| | Safety of human papillomavirus vaccines: a review. | Q33162724 |
| | Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience | Q33163984 |
| | Acquisition of new infection and clearance of type-specific human papillomavirus infections in female students in Busan, South Korea: a follow-up study | Q33317425 |
| | Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years | Q34014798 |
| | Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial | Q34580726 |
| | Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women | Q35154517 |
| | Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial | Q35221177 |
| | Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation | Q35498207 |
| | Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study | Q35810353 |
| | Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination | Q36978409 |
| | Current status of cervical cancer and HPV infection in Korea | Q37177794 |
| | Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial | Q38306091 |
| | Prophylactic HPV vaccination: past, present, and future | Q38597567 |
| | Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination | Q39163261 |
| | Health behaviors and related demographic factors among Korean adolescents | Q40207868 |
| | Safety and tolerability of bivalent HPV vaccine: an Italian post-licensure study | Q40336162 |
| | Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years | Q43415471 |
| | Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years | Q43452461 |
| | Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands | Q43694184 |
| | Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication | Q47860026 |
| | Comprehensive control of human papillomavirus infections and related diseases. | Q51856187 |
| | The carcinogenicity of human papillomavirus types reflects viral evolution. | Q53357731 |
| | Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. | Q54710732 |
| | Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls | Q56787280 |
| | Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine Administered According to an Alternative Dosing Schedule Compared With the Standard Dosing Schedule in Healthy Women Aged 15 to 25 Years | Q59396622 |
| | Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial | Q84532730 |
| P433 | issue | 7 | |
| P304 | page(s) | 837-842 | |
| P577 | publication date | 2017-03-07 | |
| P1433 | published in | Pharmacoepidemiology and Drug Safety | Q15759496 |
| P1476 | title | Six-year multi-centre, observational, post-marketing surveillance of the safety of the HPV-16/18 AS04-adjuvanted vaccine in women aged 10-25 years in Korea | |
| P478 | volume | 26 | |